Pharmacists have warned that one of the “worst of drug deficiency” examples is affecting cancer patients.

A pancreatic enzyme replacement helps in the therapy, craron, digestion and is essential by patients with pancreatic cancer, cystic fibrosis, and chronic pancreatitis. It is believed that more than 61,000 patients in the UK require medication.

According to the National Pharmacy Association (NPA), some patients are called “food hanging” to ration their medicine due to its deficiency.

A spokesperson for health and social care said that “European-Chauda supply issues” and it was “working closely with industry and NHS to reduce the impact on patients”.

Without drug, patients lose weight and strength, which means that their ability to deal with treatment such as chemotherapy decreases.

Some experts have predicted the ongoing decrease until next year.

The Department of Health and Social Care has increased a serious shortage protocol for Craon which is already for one year.

This indicates anxiety about a drug deficiency and allows pharmacists to give an option to patients – although they argue that other drugs are also in low supply.

A spokesman for the department said that “European-Chauda supply issues” were due to lack of supply.

The National Pharmacy Association said that more than the three quarters of the recently involved in a survey felt that the current system for management of the deficiency was insufficient.

Some reported that according to the NPA, the patients were leaving food and covering long distances to catch the medicine.

One said that it was “the worst stock shortage” that he had to deal with anytime.

BBC News highlighted the issue in February that a woman approached her saying that it was impossible for her husband, who is pancreatic cancer, to digest her food without a craron.

That month, major pancreatic physicians and charities wrote to the Prime Minister, stating that the absence of Pert could have “devastating effects on people’s lives”.

He called for a national strategy to deal with the deficiency.

Alice from Birmingham in 2023 detected pancreatic cancer and initially received 15 boxes of Craon Capsules every month to help her tolerate chemotherapy.

She can now get only six or seven and is leaving snacks.

The 64 -year -old said that Khali deeply affected his mental health.

He told the BBC: “Every day I am trying to balance: what will I eat, will I have more enough food, will I take my supplement and it makes an additional layer of stress and worries that I am trying to keep my life together again after this diagnosis.”

Pancreatic cancer UK Alphi Belly-Bearefield said that the charity had been worrying with the government and suppliers for more than a year and was important that the authorities intervened to try to promote the supply.

He said, “Thousands of people affected by pancreatic cancer rely on taking a part tablet every time to digest their food and absorb nutrients – some of us are accepted,” he said.

He said, “It is completely unacceptable that they are still taking frustrated measures that put their health, goodness and their eligibility at risk,” he said.

The Chief Executive Officer of the Independent Pharmaceutical Association, Dr. Leyla Hanback said it was very difficult for his members to get supply from wholesale traders.

He said, “The decrease with Craon has been going on for so long and it seems that no effective efforts are being made by the authorities to make the process easier for pharmacies and patients and to prioritize the availability of this product.”

“Instead they continue to prolong the current processes.”

A spokesperson for health and social care said that it knew how disappointing and harassing the “drug supply issues” could be for patients and physicians for physicians.

He said: “European-wide supply issues with Craon are due to limited availability of raw ingredients and lack of manufacturing capacity.

“We are working closely with industry and NHS to reduce the impact on patients and solve issues as soon as possible.”